30 results on '"Guo, Robin"'
Search Results
2. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
3. MET-dependent solid tumours — molecular diagnosis and targeted therapy
4. Respiratory Failure and Metabolic Acidosis Following Transurethral Resection of the Prostate
5. Abstract CT160: Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cance
6. Supplementary Data from MET Exon 14–altered Lung Cancers and MET Inhibitor Resistance
7. Potentially inappropriate medication use in elderly non‐Hodgkin lymphoma patients is associated with reduced survival and increased toxicities
8. Dysfunctional CD8+ T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC).
9. ATM-Mediated Serine 72 Phosphorylation Stabilizes Ribonucleotide Reductase Small Subunit p53R2 Protein against MDM2 to DNA Damage
10. Management of Peripheral Entrapment Neuropathy Following Abdominoplasty: A Case Report
11. Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers
12. Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas
13. MET Exon 14–altered Lung Cancers and MET Inhibitor Resistance
14. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
15. CNS Metastases in Patients With MET Exon 14–Altered Lung Cancers and Outcomes With Crizotinib
16. Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC).
17. Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
18. Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
19. Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
20. MET inhibitor resistance in patients with MET exon 14-altered lung cancers.
21. Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities
22. Polypharmacy and potentially inappropriate medication use in older patients with aggressive non-Hodgkin lymphoma (NHL) leads to inferior survival and increased treatment-related toxicities.
23. Chromosomal Instability Triggered by Rrm2b Loss Leads to IL-6 Secretion and Plasmacytic Neoplasms
24. Contribution of polypharmacy and potentially inappropriate medication use to inferior survival in older patients with aggressive lymphoma.
25. Adverse impact of polypharmacy and potentially inappropriate medication use in newly diagnosed, elderly lymphoma patients.
26. MET IHC Is a Poor Screen for METAmplification or METExon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
27. Potentially Inappropriate Medication Use in Elderly Patients with Diffuse Large B-Cell Lymphoma Predicts Inferior Survival and Treatment-Related Toxicities
28. Canonical Nuclear Factor κB Pathway Links Tumorigenesis of Synchronous Mantle-Cell Lymphoma, Clear-Cell Renal-Cell Carcinoma, and GI Stromal Tumor
29. ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage.
30. Contribution of polypharmacy and potentially inappropriate medication use to inferior survival in older patients with aggressive lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.